Products - Oesophageal cancer | Topic | NICE

Showing 11 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 January 2027
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 February 2027
Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett’s oesophagus [ID6683]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 February 2027
Suspected cancer update
Status:
In development
Expected publication date:
TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
15 June 2026
Expected publication date:
TBC